Regulatory T cell: a protection for tumour cells

Yi Wang #, Yushui Ma #, Ying Fang, Shengdi Wu, Lili Liu, Da Fu *, Xizhong Shen *

The Department of Gastroenterology of Zhongshan Hospital, Fudan University, Shanghai, China

Received: June 02, 2011; Accepted: August 04, 2011

Abstract

Characterized by immunosuppression regulatory T cells (Tregs) play a key role in maintaining immune tolerance. A growing number of tumours have been found with Tregs accumulating in microenvironment and patients with high density of Tregs in tumour stroma get a worse prognosis, which suggests that Tregs may inhibit anti-tumour immunity in stroma, resulting in a poor prognosis. In this paper, we demonstrate the accumulation of Tregs in tumour stroma and the possible suppressive mechanisms. We also state the immunotherapy that has being used in animal and clinical trials.

Keywords: Tregs ● TGF-β ● IL-10 ● Foxp3

Introduction

The concept of Tregs, called as suppressor T cells [1], was firstly mentioned by Gershon in 1970s. However the suppressor T cells were not successfully isolated for a lack of a reliable marker. Until 1995 Sakaguchi et al. firstly reported that depleting CD4+CD25+ T lymphocytes by CD25 monoclonal antibody would induce multiple organs affected autoimmune diseases and reconstitution of those cells significantly prevented diseases development [2]. Since then CD4+CD25+ T lymphocytes have been described as Tregs and soon afterwards the discovery of transcription factor forkhead box P3 (Foxp3) provided us a better marker for identification of Tregs [3]. There are two major subsets of Tregs, naturally occurring regulatory T cells and antigen-induced regulatory T cells. Recently, another type of regulatory T cells originated from CD8+ T cells have been reported by Suzuki [4]. But the function of these cells is still controversial.

Owing to the immunosuppression more and more autoimmune diseases and chronic inflammation have been found correlating to the disfunction or decreasing of Tregs in vivo, such as inflammatory bowel disease [5], systemic lupus erythematosus [6], multiple sclerosis (MS) [7], viral hepatitis type B [8] and so on. Secreting immunosuppressive cytokines and cell-to-cell connection has been generally acknowledged as the major manner to mediate immune tolerance. Tregs not only take part in the developing of autoimmune diseases, but also influence the prognosis of patients with cancer.

Many tumours have been found with an increasing Tregs in tumour stroma, for example, breast cancer [9], hepatocellular carcinoma...
The immunosuppression of Tregs to natural killer (NK) cells, CD8+ T cells and antigen presenting cells has been considered as the major manner which helps tumour cells escaping from immune surveillance. More recently Tregs obtain unprecedented attention in the world; more and more scientists and doctors are intrigued in this field. In this paper, we summarize recent data which focus on Tregs trafficking, immunosuppression and treatment in patients with tumours.

The mechanisms of Tregs stimulating metastasis and mediating immunosuppression

Tregs are essential to self-tolerance and homeostasis, and they can even stimulate metastasis directly [13]. Tregs perform immunosuppression in tumour via connection and non-connection manners. Suppressive cytokines produced by Tregs such as transforming growth factor-β (TGF-β) and Interleukin-10 (IL-10) directly suppress immune responses [14–16]. However, the cell surface ligands cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and glucocorticoid-induced tumour-necrosis factor-receptor related protein (GITR) can also mediate immunosuppression [17, 18] (Fig. 1).

Tregs stimulate cancer metastasis through RANKL-RANK signal

As mentioned earlier, an enhanced frequency of Tregs were found in peripheral blood and tumour stroma of several tumours. It has been controversial for a long period of time whether Tregs could promote tumour progression directly. But the recent studies have
confirmed that Tregs can mediate metastasis by receptor activator of nuclear factor-κB ligand (RANKL)-RANK signal [13]. Maspin is the unique member of serpin family characterized by inhibiting tumour angiogenesis. Zhang et al. reported that transferring Maspin gene into human prostate tumour could effectively inhibit tumour growth in mice and reduce the tumour microvessel [19]. However, tumour infiltrating cells expressed RANKL, which inhibited Maspin transcription and promote cancer metastasis [20]. More recently, Tan et al. have shown that Tregs were the major source of RANKL and stimulated pulmonary metastasis of human breast cancer. Blocking RANK signalling might prevent the recurrence of metastasis after surgical operation [13]. As a potential immunotherapeutic target RANK–RANKL signal pathway should merit further investigation.

**TGF-β inhibits anti-tumour immunity in tumour microenvironment**

Transforming growth factor-β is an essential for Tregs-mediated immune tolerance. In tumour microenvironment including Tregs, tumour cells, macrophages, endothelial, mesenchymal cells and myeloid precursor cells are the major sources of TGF-β [21]. The major function of TGF-β is to maintain self-tolerance and inhibit immune responses [22]. Nearly all of haemocytes are influenced by TGF-β in vivo, for example, T lymphocytes, B lymphocytes, NKs, dendritic cells (DCs), macrophages. Transforming growth factor-β could inhibit proliferation, differentiation and maturation of T lymphocytes or B lymphocytes [22, 23]. NKs play a key role in anti-tumour immunity by lysis, but Tregs can also suppress their cytotoxicity to tumour cells by TGF-β manner [24]. Antigen presenting cells are essential for activating body anti-tumour immunity through expressing co-stimulatory molecules. However, Tregs inhibit DCs and macrophages expressing co-stimulatory molecules by secreting TGF-β, and attenuate body anti-tumour immunity [25, 26]. But Nakamura et al. reported that surface binding TGF-β of Tregs but not secreting TGF-β mediated the suppression [27].

**Immunosuppression of Tregs can be abolished by neutralized or knocked out IL-10**

Interleukin-10 is another immunosuppressive cytokine secreted by Tregs [16]. Binding to receptor on membrane surface IL-10 transfer signal into cytoplasm and phosphorylate signal transducers and activators of transduction 3 (STAT3). Signal transducers and activators of transduction heterodimers subsequently transfer into nucleus and interact with IL-10 responsive gene [28]. Animal experiment has proved that transferring Tregs from wild-type mice but not from IL-10 deficient mice can resolve establishment colitis [29]. Interleukin-10 not only participates in the process of autoimmune diseases, but also weakens immune surveillance. In tumour models knocking out IL-10 gene or blocking IL-10 receptor dramatically activate CD8⁺ T cells–mediated anti-tumour responses in vivo [30]. Similarly, in patients with head and neck squamous cell carcinoma Tregs isolated from tumour-mediated stronger suppression than those from healthy people [31]. Moreover, neutralizing IL-10 completely abrogated suppression of those cells in vitro [31]. Undoubtedly, IL-10 is a very important suppressor factor secreted by Tregs.

**CTLA-4 participates in the suppression of Tregs**

Cytotoxic T lymphocyte–associated antigen 4 is constitutively expressed on CD4⁺CD25⁺ regulatory T cells and plays a pivotal role in T lymphocytes–mediated immune responses [18]. Blocking CTLA-4 will induce chronic organ specific autoimmune diseases such as inflammatory bowel disease, diabetes and so on [32, 33]. The activation of T lymphocytes is a complex procedure, which needs stimuli from major histocompatibility complex (MHC) and B7 family members. Only when T cell receptor (TCR) and CD28 are triggered could T lymphocyte be fully activated. However, CTLA-4, the homologue of CD28, competitively binds to B7 family members and blocks the interaction between CD28 and B7. In contrast to CD28 pathway, CTLA-4 transfers a negative signal into peripheral T cells and decreases the production of IL-2, which is a very important cytokine to stimulate T cells proliferation [34]. In the absence of CTLA-4 peripheral T cells show a marked proliferation and secretion. Furthermore, most cell cycle progressions are prolonged and keep in the S and G2-M phase [35]. Animal experiment has also proved that knocking out mouse CTLA-4 gene would induce sever multiple organ lymphocytic infiltration and die in 3–4 weeks [36]. However, transplanting bone marrow from wide-type mouse into CTLA-4 deficient mouse displayed an amazing result as multiple organs inflammation disappeared and the mouse’s lifetimes were prolonged [37]. Cytotoxic T lymphocyte–associated antigen 4 is an indispensable inhibitory receptor for Tregs. Blocking CTLA-4 is an important manner to break immune tolerance and many experiments have shown that it is efficacy to treat cancer patients [38, 39].

**Blocking GITR weakens the immunosuppression of Tregs**

Glucocorticoid-induced tumour-necrosis factor–nerve growth factor (TNF–NGF) receptor and predominantly expressed on CD4⁺CD25⁺ regulatory T cells [17]. It has been proved that blocking GITR in vivo will induce severe autoimmune diseases of model mouse [40, 41]. Administration of anti-GITR monoclonal antibody to tumour-bearing mouse could provoke anti-tumour immunity and lead to the regression of tumours. Furthermore, there were more infiltrating CD4⁺ and CD8⁺ T cells in treated tumours than control [42]. Because in some conditions GITR could induce T cells proliferation [43], the mechanism of
GITR-mediating negative regulation is still not clear. One possible explanation is that GITR located on the membrane of Tregs has a higher affinity to bind with GITRL, which competitive inhibit GITRL connecting with GITR on effector T cells.

Others

With the advent of researching, more and more mechanisms have been found to relating to the negative regulation of Tregs. For example, IL-35 is a newly discovered cytokine, which is characterized by negative regulation. It is one of the family members of IL-27 and a heterodimer consisted with IL-27β and IL-12β subunits [44, 45]. As a newly found inhibitory cytokine IL-35 plays a principal role in keeping immune homeostasis. It can suppress proliferation of conventional T cells collaborating with IL-10 [44]. Tregs isolated from IL-35 knockout mouse had a significantly reduced negative regulation and failed to control inflammatory bowel disease [45]. Moreover, recent studies have confirmed that IL-35 is another one important cytokine-mediated immunosuppression in tumour microenvironment [46].

CD39, an ectoenzyme binding on membrane of Tregs, can mediate immune suppression by catalysing adenosine generation. Tregs isolated from CD39 knockout mouse have an impaired negative regulation [47]. Compared with mouse, CD39 is restricted to a subset of Foxp3+ regulatory T cells and decreases significantly in patients with relapsing form of MS [48]. The decreasing of CD39 may be the major cause leading to impair suppressive capacity of Tregs. In addition, apoptosis induced by perforin/granzyme A and B manner is another way to mediate suppression by regulatory T cells in human and murine [49, 50]. Tregs consumed abundant IL-2 in microenvironment via CD25 and induce cytokine deprivation mediated apoptosis of effector T cells [51].

The manners of Tregs in tumour stroma

A growing number of tumours, such as hepatocellular carcinoma [10], colon carcinoma [12], ovarian cancer [52] and breast cancer [9], have been found to have a microenvironment with high frequency of Foxp3-positive cells. Moreover, patients with high Tregs usually have a poor survival than the lower ones. Proliferation, recruitment and conversion are considered to be the major ways that contribute to the accumulation of Tregs in tumours (Fig. 2).

Tregs proliferate in tumour microenvironment

In tumour microenvironment, Tregs play a key role in suppressing effector T cells. However, a subset of myeloid DCs in tumours could be converted into regulatory DCs characterized by secreting bioactive TGF-β and mediated proliferation of naturally occurring Tregs [53]. Coe et al. reported that tumour antigen contributed to the expansion of natural regulatory T cells in tumour and CD11c+ cells purified from tumour-draining lymph nodes were the key cells involved in the antigen-presenting process. Moreover, TGF-β expressed by tumour cells was also responsible for the expansion of Tregs [54]. On the one hand, expansion induces a high density of Tregs in tumour stroma; on the other hand, the increasing Tregs abrogate anti-tumour immunity in vivo, resulting in a poor prognosis. Therefore, blocking the proliferation might improve the survival of patients with tumour.

Tumours secrete chemokines recruiting Tregs from peripheral blood

Chemokine is a big family, which mediates lymphocyte and granulocyte migrating from peripheral blood into damaged tissues, especially in inflammatory condition. Plenty of tumours are found to secrete chemokines such as stromal cell-derived factor-1 (SDF-1/CXCL12), thymus and activation-regulated chemokine (TARC/CCL17), macrophage-derived chemokine (MDC/CCL22) and so on [55, 56]. In tumour stroma, chemokines not only regulate neoplasm metastasis, but also mediate Tregs homing [57]. Tregs functionally express CCR4, the unique receptor of CCL22, and recruit from peripheral blood into solid tumours [58]. Through the interaction Tregs are trafficked and activated in tumour stroma [59]. Moreover, Mizukami reported that the migration could be significantly abrogated by CCL22 neutralizing antibody [56]. It proves from negative side that chemokine really contribute to Tregs homing.

Non-regulatory T cells converse into Tregs in tumour stroma

Accumulating evidences have shown that Tregs can be converted from non-regulatory T cells in vivo and in vitro [60–63]. Conversion is another important reason to induce increasing frequency of Tregs in tumour microenvironment. Several kinds of cytokines and immune cells join in the process, such as TGF-β, IL-2, retinoic acid (RA), DCs and macrophage [62–64]. As a considerable negative regulator TGF-β is the first cytokine confirmed with Foxp3 inducible function [60]. In microenvironment tumour cells could interact with APCs and enhance the secretion of TGF-β. Under the action of TGF-β, CD4+Foxp3+ T cells are converted into CD4+Foxp3+ regulatory T cells. Nevertheless, neutralizing antibody thoroughly could abrogate the inducible function of TGF-β [65].

Retinoic acid is a newly found factor, which could induce the expression of Foxp3 gene in CD4+Foxp3+ T cells, and synthetic RA receptor inhibitors block the expression of Foxp3 gene, suggesting that RA, the metabolin of vitamin A, is essential for the conversion of Tregs in vitro [61]. In addition, macrophage is also related to the increased intratumoural Tregs via serum section authors found that patients with high intratumoural macrophage density tended to
have more Tregs than those with low macrophage density and depletion of macrophage effective decreased the density of Foxp3 positive cells in tumour stroma [63]. But the exact link between macrophage and Tregs is still elusive.

The target cells of Tregs in tumour microenvironment

The major roles Tregs plays in \textit{in vivo} are keeping homeostasis and inhibiting severe immune responses. Most of immune cells in the tumour stroma, such as T lymphocytes, B lymphocytes, NK, DCs, macrophage, are targets of Tregs [66–71]. Redundant Tregs accumulating in a tumour not only keep homeostasis, but also restrain local anti-tumour immunity (Fig. 3). Because of the suppression, tumour cells evade from body immune surveillance, hence a poor prognosis.

Tregs weaken body immune surveillance by inhibiting DCs

Dendritic cells are the most considerable professional antigen presenting cells \textit{in vivo} and play a critical role in defence of infection and tumour. There are two major subsets of DCs widely distributed in organs and lymphatic tissues, myeloid DCs and lymphoid DCs [72]. In tumour microenvironment, DCs migrate from tumour into lymph nodes and mature with the tumour antigen stimuli. In this process, DCs capture antigen and form peptide–MHC complexes on cell surface. Meanwhile, the expression of co-stimulatory and adhesion molecules is also enhanced. Major histocompatibility complex complexes interact with TCR and provide the first signal for T cell activation. Co-stimulatory molecules that bind to respective receptors on T cells, including CD80, CD83, CD86, provide the second signal to activate T cells. Both of the two signals are needed in stimulating T cells proliferation and activation.

But DCs are an important target of Tregs in tumour stroma. Inhibiting the expression of co-stimulatory molecules is one of most important ways to suppress DCs. Most of co-stimulatory molecules expressing on DCs surface, such as CD80, CD83, CD86 and so on, significantly low regulate during co-culture with Tregs [67, 69]. Lack of stimulation from co-stimulatory molecules T cells can not be activated sufficiently and body immune surveillance is significantly impaired. Although TGF-β and IL-10 secreted by Tregs mediate the suppression, cell-to-cell connection should not be ignored [67]. Previously, several clinical trials were conducted to treat patients with cancer by DCs vaccines, but no firm conclusions were yielded [73]. Therefore, Tregs can be one of the key contributing factors to weak immunotherapy of DCs vaccines \textit{in vivo}, which merits further investigation.
Indoleamine 2,3-dioxygenase (IDO) expressed by DCs is capable of suppressing proliferation of T cells in vitro. Via engagement by CTLA-4 situate on Tregs the expressing of IDO could be trigged [74]. In addition, IDO expressing mature monocyte-derived DCs expanded autologous Tregs [75]. Even in suitable conditions DCs could promote the conversion of naive T cells into Foxp3⁺ regulatory T cells [61]. It becomes an infernal circle and weakens the antigen presenting of DCs.

**Tregs suppress non-regulatory CD4⁺ T cells**

T cells-mediated immune responses is an important part of anti-tumour immunity in vivo. Non-regulatory CD4⁺ T cells are a major subset of peripheral blood T cells and play an important supporting role in tumour immunity. After peptide–MHC II complexes and co-stimulatory molecules double stimulating, those cells are activated and secrete plenty of cytokines such as IL-2, interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α) and so on. CD4⁺ T cells mediate the function of CD8⁺ T cells, NKs and DCs via releasing of cytokines and cell-to-cell connection [76–78].

Although Tregs are also a part of CD4⁺ T cells, they have completely different function in vivo or in vitro. Tregs, especially infiltrating into tumour stroma, significantly inhibit CD4⁺CD25⁺ effector T cells activation and releasing cytokines, which suppress tumour immunity directly [79, 80]. During the suppression CTLA-4, IL-10, TGF-β and other factors play a vital important role [16, 22]. In addition, CD4⁺Foxp3⁻ T cells can be convened into CD4⁺Foxp3⁺ regulatory T cells, which is another significant manner to help tumour cells escape from immune surveillance.

**Tregs inhibit the proliferation and anti-tumour capacity of CD8⁺ T cells**

CD8⁺ T cells, characterized by anti-tumour, are the most important source of CTL in vivo. MHC-I and B7 are two necessary signals to activate CD8⁺ T cells. After stimulating and interacting with CD4⁺ T cells, CD8⁺ T cells converse into CTL. CD8⁺ CTL-mediated tumour cell lysis include three major manners: granule exocytosis, Fas/Fas ligand (FasL) death pathway and releasing cytokines [81–83]. Through granule exocytosis, perforin and

---

**Fig. 3** The target cells of regulatory T cells. By secreting inhibitory cytokines and expressing suppressive receptor, regulatory T cells not only keep homeostasis in vivo, but also inhibit immune surveillance in tumour microenvironment. Regulatory T cells nearly suppress all of lymphocytes, including T cells, B cells, NKs, DCs, and macrophage (Mac). Because of the suppression, anti-tumour immunity is significantly weakened.
Tregs suppress the lysis of NK cells

Although NKs possess little frequency of peripheral lymphocytes, it plays a key role in anti-tumour immunity. Natural cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC) and cytokine production are considered the principle manners which mediate the lysis of NKs. MHC-I molecules transmit an inhibitory signal to NKs via killer cell inhibitory receptors (KIR). Moreover, killer cell activating receptors (KAR) expressed on NKs surface transmit an opposite signal. The balance between inhibitory and activating signals determines the cytotoxicity of NKs. In contrast to normal cells, some tumour cells generally low express MHC-I molecules, which break the balance and activate the lysis of NKs [24].

Similar to T cells, NKs are also sensitive to the immune suppression of Tregs. Tregs not only inhibit proliferation of NKs, but also suppress cytokines production and activation [70, 87, 88]. Via expressing IFN-γ and perforin NKs mediate the target cell lysis. However, co-culture with Tregs significantly decreased the expression of the both molecules [70]. In addition, natural-killer group (NKG)-2D is a crucial KAR resided on membrane of NKs and plays a pivotal role in anti-tumour immunity. But Tregs could low regulate the expression of NKG-2D by membrane binding TGF-β [87]. Because of the immune suppression of Tregs, lysis of NKs is significantly impaired and helps tumour cells escape from immune surveillance.

Tregs inhibit the proliferation of B cells

B lymphocytes are another kind of APCs in vivo and also express co-stimulatory molecules. As in the case of DCs, B cells are effective antigen presenting cells and mediate tumour immunity in vitro [89]. However, only activated B cells could effectively stimulate CD4+ T cells, resting B cells even block anti-tumour responses in vivo [90, 91]. Tregs can also suppress the function of B cells and influence tumour immunity mediated by B cells. Shevch et al. reported that Tregs directly suppressed B cells proliferation and increased the death of the cells by cell-to-cell connection [71]. Otherwise, Tregs directly inhibited Ig production in B cells, which also demonstrated the suppressive relationship between Tregs and B cells [92].

Tregs inhibit function of macrophage directly

Although many studies showed that macrophage infiltrating in tumour produces a negative effect on prognosis [93, 94]. As an important member of professional APC, macrophage also participates in the body anti-tumour immunity. Macrophage potentially functions in anti-tumour immunity by directly killing cancer cells, presenting tumour-associated antigens and secreting cytokines [95]. Moreover, some results have shown that patients with high macrophage density in tumour get improved prognosis [96, 97]. But there is little literature on the relationship between Tregs and macrophage. Gerwenka et al. reported that Tregs depletion in mice led to tumour rejection and macrophage accumulation [98], suggesting that Tregs in tumour might inhibit macrophage migrating into tumour stroma. In addition, co-culture with Tregs induced minimal cytokine production and limited up-regulation of CD40, CD80 and CD86 in monocyte/macrophage [68]. Inextricably, there is a close link between macrophage and Tregs.

A new immunotherapeutic target

We have demonstrated a negative connection between Tregs and human cancer. Because of the immunosuppression Tregs have become another prospective therapeutic target. Many drugs and antibodies for depletion those cells have been designed and applied in clinical trials including cyclophosphamide, anti-CD25 antibody, anti-GITR antibody, denileukin diftitox and so on. Eliminating Tregs can inhibit tumour growth or even trigger tumour regression, especially in some animal models [99–102], and blocking Tregs may break immune tolerance and activate anti-tumour immunity, as indicated by some clinical favourable results [39, 103].

Depletion of Tregs leads to tumour regression

As a common agent, cyclophosphamide is mainly used for the treatment of malignant cancer and autoimmune diseases. It can effectively inhibit synthesis of DNA and induce apoptosis of target cells. Animal experiments show that cyclophosphamide can directly deplete Tregs and improve outcome of tumour-bearing animals [104]. Although animal experiments have achieved exciting results, the outcomes of clinical trials are not consistent with each other [105, 106]. It is still controversial that whether cyclophosphamide can decrease the frequency of Tregs or improve prognosis in human patients. As a specific marker of Tregs, CD25 has become a therapeutic target for depletion of those cells. Several studies have indicated that administration of anti-CD25 mAb significantly prevented tumour growth or even got tumour regression in mouse [99–102]. Denileukin diftitox (ONTAK) is a novel recombinant fusion protein characterized by a fragment of diphtheria toxin linked to human interleukin-2 [107].
It was first used to treat cutaneous T cell lymphoma and acquired satisfactory responses [103]. Thanks to the significant depletion of Tregs in circulating pool, doctors tried it in treating patients with melanoma and obtained favourable results [108].

Although eliminating regulatory T cells have shown a potential immunotherapy for cancer treatment, the shortcomings are also obvious. Firstly, some effector cells can also express CD25, and administration of CD25 mAb may induce the depletion of CD25-positive effector T cells and impair anti-tumour immunity [109]. Secondly, Tregs elimination breaks self-tolerance and leads to autoimmune diseases [2]. Tregs are clearly an important target for immunotherapy, but not the best choice. The only effective solution depends on the discovery of more specific markers.

**Inhibiting the immunosuppression of Tregs improves the prognosis of cancer patients**

Glucocorticoid-induced tumour-necrosis factor-receptor related protein and Cytotoxic T lymphocyte–associated antigen 4 are the significant immunosuppressive receptors located on Tregs membrane. Because of the immunosuppression, those receptors have become a new target to attenuate the function of Tregs. Several studies have reported the potential efficiency to treat tumour with agonistic anti-GITR mAb (DTA-1) and obtain favourable outcomes [42, 110]. Administration of anti-GITR mAb not only attenuated Tregs-mediated immunosuppression, but also enhanced CD4+ and CD8+ T cells infiltrating into tumour [42]. As a negative regulatory receptor CTLA-4 blockage has been proved to be another valid manner to activate anti-tumour immunity [111, 112]. It could enhance the production of IFN-γ and stimulate the anti-tumour responses in early stages of tumour growth [112]. Clinical trials have demonstrated that receiving an i.v. infusion of anti-CTLA-4 mAb, ipilimumab or tremelimumab, successfully enhanced anti-tumour immunity in patients with solid tumours [38, 39]. But adverse effects induced by anti-CTLA-4 mAb should not be ignored. Blocking those regulatory receptors efficiently weakens immunosuppression and breaks self-tolerance mediated by Tregs. Apparently, signal drug treatment is not enough for the best efficacy, with tumour vaccine to evoke efficient anti-tumour responses [113, 114]. Moreover, animal experiments have shown that vaccines combination with CTLA-4 blockage therapy is capable of eliciting anti-tumour responses and inhibiting tumour growth too [115, 116]. In addition, the similar experiment reported that using anti-GITR antibody combination with a DNA vaccine led to a more effective therapy than vaccine alone [117]. To surprise us is that several clinical trials have also proved the synergistic effect of combination therapy [113, 118]. However, we should recognize that immunotherapy is just the beginning and needs further evidence-based investigation.

**Conclusions**

Tregs accumulating in tumour stroma have been found in a growing number of tumours. Although the fact that those cells are depleted in mice shows a great prospect for tumour treatment, it is still a question whether the same results will occur in humans. Only a small percentage of patients with tumour have acquired immune responses and improved outcomes, suggesting that the depletion of Tregs by CD25 mAb or blockage inhibitory receptor is not enough to abrogate the suppression of Tregs in tumour stroma. Therefore, blocking the migration or hamper the reverse of Tregs might become a new path in breaking the tolerance in tumour microenvironment. Unfortunately, we are not sure about the exact mechanism of how Tregs accumulate into tumours. Chemokine can partially explain the recruitment of Tregs into ovarian and gastric cancer, yet it still needs further investigation to confirm whether it can produce a marked effect in other solid tumours. Similarly, TGF-β is not the only reason to explain the conversion of Tregs in tumour stroma. Thus it is still need more work to do that how CD4+ T cells convert into Tregs in tumour stroma. In spite of the difficulties we have met, we believe that with further investigation immunotherapy will become an important means of treating cancer, and that Tregs can be a good choice for immunotherapy!

**Acknowledgements**

The authors thank the team members of Prof. Shen, Xizhong’s laboratory for their helpful discussion and critical reading of the manuscript. This work was partially supported by the Ministry of Health (2009ZX10004-301), China National Key Projects for Infectious Diseases (2008ZX10002-017) and China Postdoctoral Science Foundation funded project (20100480542).

**Conflict of interest**

The authors declare that there are no conflicts of interest.
References

1. Gershon RK, Hencin R, Liebhaye SA, et al. Suppressor T cells. J Immunol. 1972; 108: 586–90.

2. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995; 155: 1151–64.

3. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4(+)/CD25(+) regulatory T cells. Nat Immunol. 2003; 4: 330–6.

4. Rifa’i M, Kawamoto Y, Nakashima I, et al. Essential roles of CD8(+)CD122(+) regulatory T cells in the maintenance of T cell homeostasis. J Exp Med. 2004; 200: 1123–34.

5. Maut J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005; 128: 1688–73.

6. Valencia X, Yarboro C, Illei G, et al. Deficient CD4(+)/CD25(high) regulatory T cell function in patients with active systemic lupus erythematosus. J Immunol. 2007; 178: 2579–86.

7. Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4(+)CD25(+) regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199: 971–9.

8. Xu DP, Fu JL, Jin L, et al. Circulating and liver resident CD4(+)CD25(+) regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B-1. J Immunol. 2006; 177: 739–47.

9. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24: 5373–80.

10. Gao Q, Qiu SJ, Fan J, et al. Intratumoural balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma reversion after resection. J Clin Oncol. 2007; 25: 2586–93.

11. Salama P, Phillips M, Grieu F, et al. Tumour-infiltrating FOXP3(+) T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009; 27: 186–92.

12. Sinicrope FA, Rego RL, Ansell SM, et al. Intraepithelial effector (CD3(+)regulatory (FoxP3(+)) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009; 137: 270–9.

13. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate malignant cancer metastasis through RANKL–RANK signalling. Nature. 2011; 470: 549–53.

14. Dieckmann D, Plotthner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4(+)/CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001; 193: 1303–10.

15. Jonuleit H, Schmitt E, Käkkinen H, et al. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med. 2002; 196: 255–60.

16. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008; 8: 523–32.

17. Shimizu J, Yamazaki S, Takahashi T, et al. Stimulation of CD25+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002; 3: 135–42.

18. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by Foxp3 programs the development and properties from human blood. J Exp Med. 2004; 200: 1123–34.

19. Zhang M, Volpert O, Shi YH, et al. Maspin is an angiogenesis inhibitor. Nat Med. 2000; 6: 196–9.

20. Luo JL, Tan W, Riccom GM, et al. Nuclear cytokine-activated IKK alpha controls prostate cancer metastasis by suppressing Maspin. Nature. 2007; 446: 690–4.

21. Massague J. TGF beta in cancer. Cell. 2003; 104: 215–30.

22. Li MO, Yan Y, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006; 24: 99–146.

23. Gorelik L, Flavell RA. Transforming growth-factor-beta in T-cell biology. Nat Rev Immunol. 2002; 2: 46–53.

24. Ralainirina N, Poli A, Michel T, et al. Control of NK cell functions by CD4(+)/CD25(+) regulatory T cells. J Leukocyte Biol. 2007; 81: 144–53.

25. Cederbom L, Hall H, Ivars F. CD4(+)/CD25(+) regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol. 2000; 30: 1538–43.

26. Takeuchi M, Alard P, Streilein JW. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J Immunol. 1998; 160: 1589–97.

27. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)/CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001; 194: 629–44.

28. Lai CF, Ripperger J, Morella K, et al. Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J Biol Chem. 1996; 271: 13968–75.

29. Uhlig HH, Coombs J, Motett C, et al. Characterization of Foxp3(+)CD4(+)CD25(+) and IL-10-secreting CD4(+)CD25(+) T cells during cure of colitis. J Immunol. 2006; 177: 5852–60.

30. Dercamp C, Chemin K, Caux C, et al. Distinct and overlapping roles of interleukin-10 and CD25(+) regulatory T cells in the inhibition of antitumour CD8 T-cell responses. Cancer Res. 2005; 65: 8479–86.

31. Strauss L, Bergmann C, Szczepanski M, et al. A unique subset of CD4+CD25(high)Foxp3+ T cells secreting interleukin-10 and transforming growth factor-beta mediates suppression in the tumour microenvironment. Clin Cancer Res. 2007; 1: 4345–54.

32. Araki M, Chung D, Liu S, et al. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 Type 1 diabetes model in nonobese diabetic mice. J Immunol. 2009; 183: 5146–57.

33. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000; 192: 295–302.

34. Wulunus TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996; 183: 2541–50.

35. Greenwald RJ, Oosterwegel MA, van der Woude D, et al. CTLA-4 regulates cellular responses. J Cell. Mol. Med. Vol 16, No 3, 2012

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
433
tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity.* 1995; 3: 541–7.

37. Bachmann MF, Kohler G, Eacart B, *et al.* Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. *J Immunol.* 1999; 163: 1128–31.

38. O’Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4)—a novel strategy for the treatment of melanoma and other malignancies. *Cancer.* 2007; 110: 2614–27.

39. Ronchetti S, Zollo O, Bruscoli S, *et al.* Human T regulatory cells can use the perforin pathway to cause autologous target cell death. *Immunity.* 2004; 21: 589–601.

40. Kohm AP, Williams JS, Miller SD. Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4(+) T cell activation and experimental autoimmune encephalomyelitis. *J Immunol.* 2004; 172: 4686–90.

41. Morris GP, Kong YCM. Interference with CD4(+) CD25(+) T-cell-mediated tolerance to experimental autoimmune thyroiditis by glucocorticoid-induced tumour necrosis factor receptor monochlonal antibody. *J Autoimmun.* 2006; 26: 24–31.

42. Ke K, Yamazaki S, Nakamura K, *et al.* Treatment of advanced tumours with agonistic anti-GITR mAb and its effects on tumour-infiltrating Foxp3(+)CD25(+)CD4(+) regulatory T cells. *J Exp Med.* 2005; 202: 885–91.

43. Ronchetti S, Zollo O, Bruscoli S, *et al.* GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. *Eur J Immunol.* 2004; 34: 613–22.

44. Collison LW, Pillai MR, Chaturvedi V, *et al.* Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. *J Immunol.* 2009; 182: 6121–8.

45. Collison LW, Workman CJ, Kuo TT, *et al.* The inhibitory cytokine IL-35 contributes to regulatory T-cell function. *Nature.* 2007; 450: 566–619.

46. Collison LW, Chaturvedi V, Henderson AL, *et al.* IL-35-mediated induction of a potent regulatory T cell population. *Nat Immunol.* 2010; 11: 1093–101.

47. Deagleio S, Dwyer KM, Gao W, *et al.* Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med.* 2007; 204: 1257–65.

48. Borsellino G, Kleinviechtfeld M, Di Mitri D, *et al.* Expression of ectonucleotidase CD39 by Foxp3(+) Treg cells: hydrolysis of extracellular ATP and immune suppression. *Blood.* 2007; 110: 1225–32.

49. Gongde DC, Lu LF, Quezada SA, *et al.* Cutting edge: contact-mediated suppression by CD4(+)CD25(+) regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. *J Immunol.* 2005; 174: 1783–6.

50. Grossman WJ, Verbsky JW, Barchet W, *et al.* Human T regulatory cells can use the perforin pathway to cause autologous target cell death. *Immunity.* 2004; 21: 589–601.

51. Pandiyan P, Zheng LX, Ishihara S, *et al.* CD4(+) CD25(+)Foxp3(+) regulatory T cells induce cytokine deprivation mediated apoptosis of effector CD4(+) T cells. *Nat Immunol.* 2007; 8: 1353–62.

52. Wolf D, Wolf AM, Rumpold H, *et al.* The expression of the regulatory T cell-specific forkhead box transcription factor Foxp3 is associated with poor prognosis in ovarian cancer. *Clin Cancer Res.* 2005; 11: 8326–31.

53. Ghiringhelli F, Puig PE, Roux S, *et al.* Tumour cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4(+)CD25(+) regulatory T cell proliferation. *J Exp Med.* 2005; 202: 919–29.

54. Cio C, Addy C, White M, *et al.* The roles of antigen-specificity, responsiveness to transforming growth factor-beta and antigen-presenting cell subsets in tumour-induced expansion of regulatory T cells. *Immunology,* 2010; 131: 556–69.

55. Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. *Cancer Lett.* 2006; 238: 30–41.

56. Mizukami Y, Kono K, Kawaguchi Y, *et al.* Tumour cells in gastric cancer. *Int J Cancer.* 2008; 122: 2286–93.

57. Ruffini PA, Morandi P, Cabioglu N, *et al.* Manipulating the chemokine-chemokine receptor network to treat cancer. *Cancer.* 2007; 109: 2392–404.

58. Curiel TJ, Coukos G, Zou LH, *et al.* Tumour-derived CD4(+)CD25(+) regulatory T cells promote the differentiation of CD4(+)CD25(+)Foxp3(+) regulatory T cells in an adenovirus-mediated TGF-beta-induced tumor-suppressive microenvironment. *Cancer Res.* 2007; 67: 6854–60.

59. Misra N, Bayry J, Lacroix-Desmazes S, *et al.* Cutting edge: human CD4(+)CD25(+) T cells restrain the maturation and antigen-presenting function of dendritic cells. *J Immunol.* 2004; 172: 4676–80.
70. Trzonowski P, Szmit E, Mysielska J, et al. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol. 2004; 112: 258–67.

71. Zhao DM, Thornton AM, DiPaolo RJ, et al. Activated CD4 (+)CD25 (+) T cells selectively kill B lymphocytes. Blood. 2006; 107: 3925–32.

72. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002; 2: 151–61.

73. Lee DC, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immun. 2004; 53: 275–306.

74. Munn DH, Sharma MD, Mellor AL. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. J Immunol. 2009; 182: 4100–10.

75. Chung DJ, Rossi M, Romano E, et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004; 172: 4100–10.

76. Janssen EM, Lemmens EE, Wolfe T, et al. CD4(+)/CD25(+) T cells are required for secondary expansion and memory in CD8(+) T lymphocytes. Nature. 2003; 421: 852–6.

77. Toes REM, Ossevoort F, Offringa R, et al. CD4 T cells and their role in antitumour immune responses. J Exp Med. 1999; 190: 753–63.

78. Zingoni A, Sornasse T, Cocks BG, et al. Cross-talk between activated human NK cells and CD4(+) T cells via OX40-OX40 ligand interactions. J Immunol. 2004; 173: 3716–24.

79. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008; 134: 26–37.

80. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002; 168: 4272–6.

81. Ratner A, Clark WR. Role of TNF-alpha in CD8+ cytotoxic T lymphocyte mediated lysis. J Immunol. 1993; 150: 4303–14.

82. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002; 20: 323–70.

83. Waterhouse NJ, Sutton VR, Sedelies KA, et al. Cytotoxic T lymphocyte-induced killing in the absence of granymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis. J Cell Biol. 2006; 173: 133–44.

84. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002; 2: 735–47.

85. Quesada SA, Peggs KS, Simpson TR, et al. Limited tumour infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med. 2008; 205: 2125–38.

86. Zhou Q, Bucher C, Munger ME, et al. Depletion of endogenous tumour-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009; 114: 3793–802.

87. Ghiringhelli F, Menard C, Terme M, et al. CD4(+)/CD25(+) regulatory T cells inhibit natural killer cell function in a transforming growth factor-beta-dependent manner. J Exp Med. 2005; 202: 1075–85.

88. Smyth MJ, Tong MWL, Swann J, et al. CD4(+)CD25(+) T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol. 2006; 176: 1582–7.

89. Lapointe R, Bellmoure-Pelletier A, Housseau F, et al. CD40-stimulated B lymphocytes pulsed with tumour antigens are effective antigen-presentation cells that can generate specific T cells. Cancer Res. 2003; 63: 2836–43.

90. Qin ZH, Richter G, Schuler T, et al. Cutting edge: direct suppression of B cells inhibits induction of T cell-dependent tumour immunity. Nat Med. 1998; 4: 627–30.

91. Schultz JL, Grabbe S, Von MS, DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol. 2004; 25: 659–64.

92. Lim HW, Hillsamer P, Banham HH, et al. Cutting edge: direct suppression of B cells by CD4(+)CD25(+) regulatory T cells. J Immunol. 2005; 175: 4180–3.

93. Lewis CE, Pollard JW. Distinct role of macrophages in different tumour microenvironments. Cancer Res. 2006; 66: 605–12.

94. Takenami I, Takeuchi K, Kodaira S. Tumour-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999; 57: 138–42.

95. Klimp AH, Vries EGE, Scherpohl GL, et al. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hema. 2002; 44: 143–61.

96. Forssell J, Oberg A, Henriksson ML, et al. High macrophage infiltration along the tumour front correlates with improved survival in colon cancer. Clin Cancer Res. 2007; 13: 1472–9.

97. Li YW, Qiu SJ, Fan J, et al. Tumour-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J Cancer Res Clin Oncol. 2009; 135: 439–49.

98. Galani IE, Wendel M, Stojanovic A, et al. Regulatory T cells control macrophage accumulation and activation in lymphoma. Int J Cancer. 2009; 127: 1131–40.

99. El Andalousi A, Lesniak MS. Prolongation of survival following depletion of CD4(+)/CD25(+) regulatory T cells in mice with experimental brain tumours. J Neurosurg. 2006; 105: 430–7.

100. Rudge G, Barrett SP, Scott B, et al. Infiltration of a mesothelioma by IFN-gamma-producing cells and tumour rejection after depletion of regulatory T cells. J Immunol. 2007; 178: 4089–96.

101. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumour immunity by removing CD25(+)CD4(+) T cells: a common basis between tumour immunity and autoimmunity. J Immunol. 1999; 163: 5211–8.

102. Viehl CT, Moore TT, Liyanage UK, et al. Depletion of CD4(+)/CD25(+) regulatory T cells promotes a tumour-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol. 2006; 13: 1252–6.

103. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001; 19: 376–88.

104. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4(+)CD25(+) regulatory T cells suppress tumour immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumours to be curative. Eur J Immunol. 2004; 34: 336–44.

105. Audia S, Nicolas A, Cathelin D, et al. Increase of CD4(+)CD25(+) regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4(+) CD25(+) T lymphocytes. Clin Exp Immunol. 2007; 150: 523–30.

106. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4(+)CD25(+) regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immun. 2007; 56: 641–8.

107. Eklund JW, Kuzel TM. Denileukin diftitox: a concise clinical review. Expert Rev Anticancer. 2005; 5: 33–8.
108. Rasku MA, Clem AL, Telang S, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med. 2008; 6: 12; doi:10.1186/1479-5876-6-12.

109. Sutmuller RPM, Van DLM, Van EA, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumour therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001; 194: 823–32.

110. Cohen AD, Diab A, Perales MA, et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumour immunity. Cancer Res. 2006; 66: 4904–12.

111. Leach DR, Krummel MF, Allison JP. Enhancement of antitumour immunity by CTLA-4 blockade. Science. 1996; 271: 1734–6.

112. Yang YF, Zou JP, Mu J, et al. Enhanced induction of antitumour T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumour-bearing stages. Cancer Res. 1997; 57: 4036–41.

113. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumour immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005; 115: 3623–33.

114. Klaqes K, Mayer CT, Lahl K, et al. Selective depletion of Foxp3(+) regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010; 70: 7788–99.

115. Davila E, Kennedy R, Celis E. Generation of antitumour immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003; 63: 3281–8.

116. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000; 60: 2444–8.

117. Hoffmann C, Stanke J, Kaufmann AM, et al. Combining T-cell vaccination and application of agonistic anti-GITR mAb (D TA-1) induces complete eradication of HPV oncogene expressing tumours in mice. J Immunother. 2010; 33: 136–45.

118. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005; 23: 741–50.